NCT00989807Approved For Marketing不适用
Expanded Access for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 4
研究概览
简要总结
This program is to provide expanded access to aztreonam lysine for inhalation (AZLI) prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 6 years of age
- •Patient has CF as diagnosed by one of the following:
- •Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test, or
- •Two well characterized genetic mutations in the CFTR gene, or
- •Abnormal nasal potential difference with accompanying symptoms characteristic of CF
- •PA present in expectorated sputum or throat swab culture within 2 months prior to consent
- •Patient must be able to provide written informed consent/assent prior to any study related procedure; parent/guardian must be able to give written informed consent as necessary prior to any study related procedure
- •At high risk for disease progression as defined by one of the following patient populations:
- •FEV1 ≤ 50 % predicted at the time of consent OR
- •Completed participation in CP-AI-006 (through Visit 20). Patients who withdraw from CP-AI-006 prior to completing all courses of AZLI and all study visits will not be eligible for this protocol.
排除标准
- •Patients with any serious or active medical or psychiatric illness that, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol or dosing requirements
- •Patients with hypersensitivity to any of the components of the drug product
- •Currently enrolled in another clinical trial
- •Pregnant or lactating females
研究者
研究点 (4)
Loading locations...
相似试验
Approved For Marketing
不适用
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway InfectionPseudomonas Aeruginosa Airway InfectionCystic FibrosisNCT00499720Gilead Sciences
进行中（未招募）
不适用
Program to Give the Drug Aztreonam Lysine for Inhalation to Patients with Cystic Fibrosis and infection by the Bacteria Pseudomonas aeruginosa Who Have Limited Treatment Options and are at Risk for Disease ProgressioAdult and paediatric cystic fibrosis (CF) patients with pulmonary Pseudomonas aeruginosa (PA) infection.EUCTR2015-000396-26-Outside-EU/EEAGilead Sciences, Inc.603
进行中（未招募）
不适用
Program to Give the Drug Aztreonamn Lysine for Inhalation to Canadian Patients with Cystic Fibrosis and infection by the Bacteria Pseudomonas aeruginosa Who Have Limited Treatment Options and are at Risk for Disease ProgressioEUCTR2015-000397-36-Outside-EU/EEAGilead Sciences, Inc.45
已完成
4 期
Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)Complication of Transplanted LungNCT01469364Duke University30
Available
不适用
Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 DeficiencyMonocarboxylate Transporter 8 DeficiencyAllan-Herndon-Dudley SyndromeNCT05911399Rare Thyroid Therapeutics International AB